Stock analyst updates for June 3 (BFRI, BIRD, BIVI, BVNRY, BYDDY, CATC, CDTX, CELZ, CEVA, CFFN)


Stock analyst updates for Friday, June 3:

Biofrontera (NASDAQ:BFRI) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Biofrontera Inc. is a biopharmaceutical company that commercializes a portfolio of pharmaceutical products for the treatment of dermatological conditions with an emphasis in the areas of photodynamic therapy and topical antibiotics. The Company’s licensed products focus on the treatment of actinic keratoses, which are precancerous skin lesions, as well as impetigo, a bacterial skin infection. Biofrontera Inc. is based in WOBURN, MA. “

All Birds (NASDAQ: BIRD) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Allbirds Inc. is a lifestyle brand with naturally derived materials to make footwear and apparel. Allbirds Inc. is based in SAN FRANCISCO. “

BioLife (NASDAQ: BIVI) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The company currently has a target price of $2.25 on the stock. According to Zacks, “BioVie Inc. is engaged in the development of drug therapies for liver disease. The Company’s product candidate includes BIV201, which is in clinical phase. BioVie Inc. is based in SANTA MONICA, California. ”

Bavarian Nordic A/S (OTCMKTS: BVNRY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and infectious disease vaccines. The Company’s product portfolio includes IMVAMUNE(R), PROSTVAC(R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

BYD (OTCMKTS: BYDDY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has a price target of $84.00 on the stock. According to Zacks, “BYD Company Limited is principally engaged in the research, development, manufacture and distribution of automobiles, secondary rechargeable batteries and mobile phone components. Its Automobiles and Related Products segment manufactures and sells automobiles, as well as automobile-related molds and components.The Company researches, develops, manufactures and sells batteries, which are applied to mobile phones, cordless phones, power tools and other kinds of portable electronic devices. Its rechargeable battery business provides lithium-ion batteries and nickel-based batteries.BYD’s Mobile Phone Components and Assembly business segment is engaged in the manufacture and sale of mobile handset components, such as housings. and keyboards; and provides assembly services. It operates mainly in China, India, Hungary and Brazil . BYD Company Limited is based in Shenzhen, People’s Republic of China. “

Cambridge Bancorp (NASDAQ:CATC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The company currently has a price target of $96.00 on the stock. According to Zacks, “Cambridge Bancorp, headquartered in Cambridge, Massachusetts, operates as a holding company of Cambridge Trust Company, which primarily offers various banking services. Its personal banking services include checking and savings accounts, ATM/debit cards, mortgages and home equity, credit cards, personal loans, certificates of deposit and account options. individual pensions, and online banking. The Company’s commercial lending business includes business credit reserve, working capital line of credit, term loans, commercial mortgage loans, SBA guaranteed loans, letters of credit and secured loans. . Cambridge Bancorp also provides commercial real estate, cash management, remote deposit capture, merchant services, healthcare professional programs and credit cards. In addition, it provides investment management, trust administration, estate settlement and financial planning services. “

Cidara Therapeutics (NASDAQ: CDTX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product portfolio includes CD101 IV, a long-acting echinocandin antifungal, topical CD101 and C001 which are undergoing various clinical trials. The company developed its product using the Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. “

Creative Medical Technology (OTCMKTS: CELZ) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have a target price of $1.00 on the stock.

CEVA (NASDAQ:CEVA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has a price target of $43.00 on the stock. According to Zacks, “CEVA is the leading licensor of signal processing intellectual property for a smarter, more connected world. They partner with semiconductor companies and OEMs around the world to create energy efficient, smart and connected devices for a range of end markets including mobile, consumer, automotive, industrial and the IoT. Their ultra-low-power IPs for vision, audio, communications and connectivity include complete DSP-based platforms for LTE/LTE-A/5G baseband processing in handsets, infrastructure and machine-to-machine devices, advanced imaging, computer vision, and deep learning for any camera-equipped device, audio/voice/speech, and always-on/ultra-low-power sensing applications for multiple IoT markets. “

Capitol Federal Financial (NASDAQ:CFFN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The company currently has a price target of $11.00 on the stock. According to Zacks, “Capitol Federal Financial is a federally chartered intermediate holding company. Capitol Federal Savings Bank is the only operating subsidiary. The bank is a community-oriented financial institution offering a variety of financial services to meet the needs of the communities we serve. They attract retail deposits from the general public and invest those funds primarily in permanent loans secured by first mortgages on owner-occupied single-family to four-family residences. “

Community Healthcare Trust (NYSE: CHCT) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Community Healthcare Trust Incorporated is engaged in acquiring properties that are leased to hospitals, physicians, health systems or other healthcare service providers. Community Healthcare Trust Incorporated is based in Franklin, USA. “

Chuy’s (NASDAQ:CHUY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Chuy’s Holdings, Inc. owns and operates full-service restaurants serving a distinct menu of authentic Mexican cuisine. The company offers a menu that includes appetizers, soups and salads, tacos, burritos, enchiladas, fajitas, and combo dishes. It operates chains across Texas, Alabama, Indiana, Kentucky and Tennessee. Chuy’s Holdings, Inc. is headquartered in Austin, Texas. “



Get news and reviews for Biofrontera Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Biofrontera Inc and related companies with MarketBeat.com’s FREE daily email newsletter.